The Quality and Outcomes Framework Exception Reporting 2009/10
QOF exception reporting 2009/10 for diabetes indicators by practice (NHS Information Centre)
Diabetic Nephropathy — A Multifaceted Target of New Therapies
With evolution in the understanding of mechanistic processes leading to DN, targeted therapies such as RAAS blockers, thiazolidinediones, statins, and fibric acid derivatives are being utilized. However the optimal treatment for DM continues to evolve as newer therapies including inhibitors of sodium glucose transport and preglycated proteins as well as antifibrotic agents are being actively investigated in decreasing DN progression (Discovery Medicine)
Strategies for Improving the Acquisition and Integration of Evidence Into Diabetes Care
By using available resources to personally examine the evidence, diabetes care providers can make informed decisions regarding ways to optimally educate and treat patients using the best practices available (Diabetes Spectrum)
Diabetes Research and Clinical Practice
Volume 90, Issue 2, Pages 131-230 (November 2010)
Metabolic Footprint of Diabetes
A Multiplatform Metabolomics Study in an Epidemiological Setting (PLoS ONE)
The impact of vitamin D deficiency on diabetes and cardiovascular risk
A review of the association between vitamin D deficiency and diabetes and cardiovascular risk (Current Opinion in Endocrinology, Diabetes & Obesity)
5-HT2CRs expressed by pro-opiomelanocortin neurons regulate insulin sensitivity in liver
Our findings indicate that 5-HT2CRs expressed by POMC neurons are physiologically relevant regulators of insulin sensitivity and glucose homeostasis in the liver (Nature Neuroscience)
Relationship between Serum Osteocalcin and Glycemic Variability in Type 2 Diabetes
Serum osteocalcin concentrations increased with improved glucose control. High initial osteocalcin levels were associated with subsequent improvements of glucose variability during glucose lowering treatment (Clinical and Experimental Pharmacology and Physiology)
External validation of the UK Prospective Diabetes Study (UKPDS) risk engine in patients with type 2 diabetes
We observed that the UKPDS risk engine overestimates CHD and CVD risk. The discriminative ability of this model is moderate, irrespective of various subgroup analyses. To enhance the prediction of CVD in patients with type 2 diabetes, this model should be updated (Diabetologia)
Glucose regulation influences treatment outcome in ranibizumab treatment for diabetic macular edema
The results of intravitreal ranibizumab injection for DME demonstrated a beneficial effect on visual acuity and a decrease in CSMT which is inversely correlated with the serum HbA1c level (Journal of Diabetes and Its Complications)
Efficacy and Harms of the Hypoglycemic Agent Pramlintide in Diabetes Mellitus
Pramlintide was somewhat more effective than placebo as adjunct therapy for improving HbA1c levels and weight in adults with type 1 diabetes on conventional insulin therapy, or type 2 diabetes and inadequate glycemic control with their current therapies. Further research is needed to determine pramlintide’s durability of hypoglycemic effect, as well as effects on patient-reported outcomes, morbidity, mortality, and long-term harms (Annals of Family Medicine)
Oramed Pharmaceuticals Presents Results of its Phase IIb Clinical Trial
This study addressing, for the first time, potential long-term safety concerns from extended ORMD-0801 administrations, demonstrated safety and no serious adverse events were reported. Poster (Oramed)
Lorcaserin Phase 3 Clinical Trial in Patients with Type 2 Diabetes Shows Statistically Significant Weight Loss
Arena Pharmaceuticals, Inc. and Eisai Inc. reported today that top-line results from the one-year lorcaserin BLOOM-DM trial demonstrate statistically significant weight loss in obese and overweight patients with type 2 diabetes (Pharmalive)
Juvenile Diabetes Research Foundation and Amylin Pharmaceuticals Partner to Investigate Metreleptin as Potential Therapy
Clinical proof-of-concept study will also evaluate whether metreleptin can reduce the amount of insulin needed by patients with type 1 diabetes (PR Newswire)
TILT
TILT (Today I Learnt That) is a free shared learning tool which allows people to easily record their clinical learning and share it with colleagues
Glycosmedia is also available as an App: